Table 4

Incremental cost-utility ratios by group

MeasureAll patientsPatients with DLS who underwent decompression alone, and the matched patients with hip or knee OAPatients with DLS who underwent decompression with fusion, and the matched patients with hip or knee OA
MIS decompression with or without fusion for DLS
n = 66
Primary THA for hip OA
n = 66
Primary TKA for knee OA
n = 66
MIS decompression for DLS
n = 35
Primary THA for hip OA
n = 35
Primary TKA for knee OA
n = 35
MIS decompression and fusion for DLS
n = 31
Primary THA for hip OA
n = 31
Primary TKA for knee OA
n = 31
Average cohort lifetime ICUR, point estimate, $/QALY794650987104504558248206987043385886
Lifetime ICUR, $/QALY (95 CI%)*8177 (8077–8277)5196 (5136–5256)7242 (7144–7340)5371 (5280–5463)6216 (6115–6318)8838 (8664–9013)10472 (10 304–10 641)4477 (4417–4537)6223 (6118–6329)
Worst-case scenario lifetime ICUR, $/QALY17062103961585012666142602329725258969215464
Best-case scenario lifetime ICUR, $/QALY320420562724195921832874356316192068
  • Note: CI = confidence interval; DLS = degenerative lumbar spondylolisthesis; ICUR = incremental cost–ulity ratios; MIS = minimally invasive surgery; OA = osteoarthritis; QALY = quality-adjusted life year; THA = total hip arthroplasty; TKA = total knee arthroplasty.

  • * Based on a probabilistic sensitivity analysis, cost and QALYs discounted at an annual rate of 3%.

  • Worst-case scenario ICUR was determined using the mean primary surgery cost plus 25%, the mean revision surgery cost plus 25%, the upper limit of the proportion of patients undergoing revision surgery, 40% inpatient rehabilitation for THA and TKA, and the lower limit of the 95% CI for QALYs gained and a 5% discount rate.

  • Best-case scenario ICUR was determined using the mean primary surgery cost minus 25%, the mean revision surgery cost minus 25%, the lower limit of the proportion of patients undergoing revision surgery, 0% inpatient rehabilitation for THA and TKA, and the upper limit of the 95% CI for QALYs gained and a 0% discount rate.